Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenelinkGNLKQ EBITDA Margin % is -197.97% as of Sep. 2013.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genelink's EBITDA for the
three
months ended in Sep. 2013 was $-0.58 Mil. Genelink's Revenue for the
three
months ended in Sep. 2013 was $0.30 Mil. Therefore, Genelink's EBITDA margin for the quarter that ended in Sep. 2013 was -197.97%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genelink EBITDA Margin % Related Terms
Genelink EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genelink's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNLKQ vs VITIF, HSTC, NTRR: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genelink's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genelink EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genelink's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genelink's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genelink (GNLKQ) has a EBITDA Margin % of -197.97% as of Sep. 2013. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genelink and its competitors.
Is Genelink's EBITDA Margin % too high?
Genelink's current EBITDA Margin % is -197.97%.
How does Genelink's EBITDA Margin % compare to VITIF and HSTC?
Genelink's EBITDA Margin % of -197.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genelink and its competitors. Genelink's current EBITDA Margin % is -197.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genelink stock overvalued right now?
Genelink (GNLKQ) has a current EBITDA Margin % of -197.97%. The current EBITDA Margin % is -197.97%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genelink (GNLKQ), the current EBITDA Margin % is -197.97% as of Sep. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNLKQ has been successfully added to your 
